Did anyone notice that the AACR presentation summary slide only referred to only overall survival (OS) benefit and not for progression-free survival (PFS)? Any thoughts?
I'm aware that OS is the primary endpoint and not PFS for the Her-Vaxx study. However, the AACR presentation indicated that there was a benefit to both OS and PFS based on the survival curves. I'm just curious as to why both aren't mentioned in the investor webinar slide.
Did anyone notice that the AACR presentation summary slide only...
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.3¢ | $615.0K | 11.39M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 2977440 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 283236 | 4 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |